Predictors of mortality in rheumatoid arthritis-associated interstitial lung disease
Joshua J. Solomon(National Jewish Health), Jeffrey J. Swigris(National Jewish Health), Gloria Russell(Pontificia Universidad Católica Madre y Maestra), Kevin K. Brown(Health Protection Surveillance Centre), Aryeh Fischer(University of Colorado Denver), M. Kristen Demoruelle(University of Colorado Denver), Tristan J. Huie(National Jewish Health), Evans R. Fernández Pérez(National Jewish Health), Jill Ketzer(National Jewish Health), Zulma X. Yunt(National Jewish Health), Amar Mannina(Creighton University), Stephen Hobbs(University of Kentucky), Gregory P. Cosgrove(National Jewish Health), Yutaka Tsuchiya(Saitama Prefecture), Pearlanne Zelarney(National Jewish Health), Jonathan H. Chung(National Jewish Health), Stephen K. Frankel(National Jewish Health), Amy L. Olson(National Jewish Health)
Cited by 393
Related Papers
Nintedanib in Progressive Fibrosing Interstitial Lung Diseases
|New England Journal of Medicine|2019|2.3k
Immunology of COVID-19: Current State of the Science
|Immunity|2020|1.8k
Efficacy and Safety of Sirolimus in Lymphangioleiomyomatosis
|New England Journal of Medicine|2011|1.1k
Diagnosis of Hypersensitivity Pneumonitis in Adults: An Official ATS/JRS/ALAT Clinical Practice Guideline
|American Journal of Respiratory and Critical Care Medicine|2020|1k
Changes in Clinical and Physiologic Variables Predict Survival in Idiopathic Pulmonary Fibrosis
|American Journal of Respiratory and Critical Care Medicine|2003|762